Oct. 12, 2023 |
|
Aug. 20, 2024 |
|
jRCT2071230061 |
A Mass Balance Study of [14C] TAS5315 in Healthy Adult Subjects |
|
A Mass Balance Study of [14C] TAS5315 in Healthy Adult Subjects |
Ali Nasermoaddeli |
||
Taiho Pharmaceutical Co., Ltd. |
||
1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo |
||
+81-3-3293-2455 |
||
th-tas5315_clinical@taiho.co.jp |
||
Suto Kotaro |
||
Taiho Pharmaceutical Co., Ltd. |
||
1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo |
||
+81-3-3293-2455 |
||
th-tas5315_clinical@taiho.co.jp |
Complete |
Oct. 30, 2023 |
||
6 | ||
Interventional |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
treatment purpose |
||
1) Aged 18 or older and younger than 40 years at the time of consent |
||
1) Had any concurrent disease (including symptoms and signs; however, diseases that do not affect evaluations in the study such as asymptomatic pollinosis and wart are excluded) |
||
18age old over | ||
40age old not | ||
Male |
||
healthy adult males |
||
Orally administration of 8 mL (containing 4 mg of TAS5315 and about 1 MBq of administered radioactivity) of the prepared solution |
||
-Plasma and blood radioactivity concentrations, plasma TAS5315 concentrations and their pharmacokinetic parameters, and blood/plasma radioactivity concentration ratio |
||
Taiho Pharmaceutical Co., Ltd. |
Hakata Clinic Institutional Review Board | |
6-18, Tenyamachi, Hakata-ku, Fukuoka City, Fukuoka | |
+81-92-283-7701 |
|
Approval | |
Oct. 13, 2023 |
No |
|
なし | |
none |